Celcuity Inc (CELC)
$16.94
Insights on Celcuity Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 273.8%
Performance
- $16.93$17.27$16.94
0.06%
Downside
Day's Volatility :1.97%
Upside
1.91%
- $8.39$22.19$16.94
50.47%
Downside
52 Weeks Volatility :62.19%
Upside
23.66%
Returns
| Period | Celcuity Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 15.71% | 1.7% | 0.0% |
6 Months | 68.56% | 11.3% | 0.0% |
1 Year | 78.5% | 5.4% | 1.3% |
3 Years | -39.48% | 13.9% | -22.1% |
Highlights
Market Capitalization | 515.9M |
Book Value | $5.48 |
Earnings Per Share (EPS) | -2.69 |
Wall Street Target Price | 28.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.56% |
Return On Equity TTM | -46.63% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -66.1M |
Diluted Eps TTM | -2.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.92 |
EPS Estimate Next Year | -3.39 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | -0.77 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 68.83%
Technicals Summary
Sell
Neutral
Buy
Celcuity Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Celcuity Inc | -4.83% | 68.56% | 78.5% | -39.48% | -21.39% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Celcuity Inc | NA | NA | NA | -2.92 | -0.47 | -0.23 | NA | 5.48 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Celcuity Inc | Buy | $515.9M | -21.39% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Morgan Stanley - Brokerage Accounts
7.21%Soleus Capital Management, L.P.
7.16%VR Adviser, LLC
6.91%COMMODORE CAPITAL LP
5.76%Perceptive Advisors LLC
4.86%NEA Management Company, LLC
4.10%
Corporate Announcements
Celcuity Inc Earnings
Celcuity Inc’s price-to-earnings ratio stands at None
Read More
Company Information
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
Organization | Celcuity Inc |
Employees | 55 |
CEO | Mr. Brian F. Sullivan |
Industry | Commercial Services |
